FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Investigation raises serious questions about the harm-benefit balance of Rexulti; the Decision may reverse efforts to reduce the use of antipsychotics in US care homes. During testing, the antipsychotic medication brexpiprazole (Rexulti) did not demonstrate a significant therapeutic effect and was

Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti

Norman DeLisle on LinkedIn: Michigan's seven-day average highest

Fast-Track Drug Approval, Designed for Emergencies, Is Now Routine

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

FDA Law Blog

Otsuka, Lundbeck bag blockbuster FDA approval for antipsychotic

How the FDA approved an antipsychotic that failed to show a

Medical Device News Update - August 2023 - Let's Talk Risk!

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Medicare coverage debates amplify as FDA approves Rexulti for

FDA Takes Tougher Line on Fast-Tracked Drugs - WSJ

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for